Tech Company Financing Transactions
Bioabsorbable Therapeutics Funding Round
On 5/10/2007, Bioabsorbable Therapeutics announced $9 million in Series B financing from Finistere Ventures, MedFocus Fund and Synergy Life Science Partners.
Transaction Overview
Company Name
Announced On
5/10/2007
Transaction Type
Venture Equity
Amount
$9,000,000
Round
Series B
Proceeds Purpose
The company will use the proceeds for continued product development and FDA approval processing.
Company Information
Company Status
Out of Business
Industry
Biopharmaceutical
Mailing Address
959 Hamilton Ave.
Menlo Park, CA 94025
USA
Menlo Park, CA 94025
USA
Phone
Website
Email Address
Not Recorded
Overview
BTI's proprietary polymers allow development of a fully bioabsorbable stent with several key advantages. The IDEAL Stent is deployed like current stents; utilizes an anti-inflammatory, therapeutic drug-delivery polymer; and permits delivery of multiple drugs with tunable release kinetics.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Pat Rivelli
Chief Medical Officer
Maurice Buchbinder
VP - R & D
Alec Piplani
Browse more venture capital transactions:
Prev: 5/10/2007: PlayPhone venture capital transaction
Next: 5/10/2007: StrataGent Life Sciences venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs